TABLE 4

Studies with clinical outcomes after fosfomycin administration for urinary tract infections published from 2010 onwardsa

First author, yr of publication (reference)Study place, yrDesignPatients, nInfectionBacteriaFosfomycin treatmentComparatorMortalityClinical cureMicrobiological cure
Ceran, 2010 (224)Turkey, NARCTFemale adults, 260Lower uUTI E. coli, Enterobacter spp.p.o. trometamol, 3-g single doseCiprofloxacin at 500 mg q12h for 5 daysNA64/77 (83%) vs 53/65 (81%)64/77 (83%) vs 51/65 (78%)
Usta, 2011 (226)Turkey, 2007–2008RCTPregnant females, 90Lower uUTI E. coli, Enterobacter spp., K. pneumoniae p.o. trometamol, 3-g single doseAmoxicillin-clavulanate at 625 mg q12h or cefuroxime at 500 mg q12hNA22/28 (79%) vs 46/56 (82%)23/28 (82%) vs 48/56 (86%)
Palou, 2013 (225)Spain, NRSB RCTPostmenopausal females, 118Lower uUTI E. coli (76.8%), K. pneumoniae (7.3%), P. mirabilis (4.9%), Enterococus spp. (3.7%)p.o. trometamol, 3 g, 2 dosesCiprofloxacin at 250mg q12h for 3 daysNA32/37 (86.5%) vs 32/39 (82.1%)23/37 (62.2%) vs 23/39 (59%)
Matsumoto, 2011 (227)Japan, 2008ProspectiveCommunity infections, 40Lower uUTI E. coli (79.5%)p.o. calcium, 1 g q8h for 2 daysNANR34/40 (85%)30/40 (75%)
Senol, 2010 (229)Turkey, 2005–2006ProspectiveCommunity infections, 47Lower cUTIESBL-producing E. coli p.o. trometamol, 3 g every other day for 3 dosesCarbapenemsNA21/27 (77.8%) vs 19/20 (95%)16/27 (59.3%) vs 16/20 (80%)
Neuner, 2012 (230)USA, 2006–2010Retrospective41UTICR K. pneumoniae (13), P. aeruginosa (8), ESBL producers (7), VRE (7), E. coli (5)p.o. in combination with other antibiotics in 27% of patientsNA4/41 (10%)NA24/41 (59%); CR K. pneumoniae, 46%; P. aeruginosa, 38%; ESBL producers, 71%; VRE, 71%
Reid, 2013 (231)USA, 2010–2011RetrospectiveKidney transplantation, 14UTIESBL-producing E. coli (7), KPC-producing K. pneumoniae (5), P. aeruginosa (2)p.o. trometamol, 3 g, median of 3 dosesNANRNA4/13 (31%); recurrence, 7/13 (54%); persistence, 3/13 (21%)
Qiao, 2013 (228)China, 2011ProspectiveCommunity infections, 356Lower UTINRp.o. trometamol, 3 g for 3 dosesNANRuUTI, 179/189 (94.7%); recurrent UTI, 61/79 (77.2%); cUTI, 42/67 (62.7%)uUTI, 83/85 (97.7%); recurrent UTI, 34/36 (94.4%); cUTI, 26/31 (83.9%)
Wu, 2014 (232)Taiwan, 2003–2013ProspectiveChildren with vesicoureteral reflux disease, 6Recurrent UTI Enterobacteriaceae, P. aeruginosa 100–200 mg/kg/day for 7–10 days plus amikacin at 15 mg/kg/day for 5 days or ceftazidime at 100–150 mg/kg/day for 7–10 daysNANR1/6 (16.7%)1/6 (16.7%)
  • a Abbreviations: CR carbapenem resistant; cUTI, complicated urinary tract infection; ESBL extended spectrum β-lactamase; KPC, Klebsiella pneumoniae carbapenemase; MDR multidrug resistant; NA, not available; NR, not reported; p.o., per os; q8h, every 8 h; RCT randomized controlled trial; SB, single blind; uUTI, uncomplicated urinary tract infections.